Latest Conference Articles

Do osteoporosis medications impact sexual function? That's what researchers aimed to find in a study presented at The North American Menopause Society 27th Annual Meeting (NAMS 2016) in Orlando, Florida.

Hadine Joffe, MD, MSc, Brigham and Women's Hospital has been trying to figure out the common menopause symptoms and how to treat them. As a psychiatrist and considering her vested interest in the brain manifestations of hormone changes, some of the symptoms she focuses on are hot flashes, sleep, and mood.

Since vitamin D plays a key role in bone mineralization, and older people tend to need more bone support, researchers looked at how providing supplementation impacted postmenopausal women.

Previous research has found that hypertension and cardiovascular health is linked to the age that a woman goes through natural menopause. A study led by researchers from the Netherlands aimed to find if blood pressure has an impact.

Adding to the seemingly endless number of reasons for keeping weight under control, a new analysis out of Brazil shows that obesity impacts menopausal symptoms.

“TX-004HR was designed to rapidly and effectively treat all symptoms of vulvar and vaginal atrophy (VVA) without increasing serum E2 levels,” a collaborative team of researchers began in a new phase 3 study.

Geography, age, and time are factors that contribute to the likelihood that a woman is being treated for menopause, according to new research out of Pfizer Inc.

Hot flashes are no stranger to 75% of women in menopause and the symptoms are severe for 15% of them.

Do sexual concerns hurt the quality of romantic relationships? Many would probably nod. But data on older women shows changes over the years.

Merck & Co., Inc. has spent years on clinical trials in hopes of submitting odanacatib to the US Food and Drug Administration (FDA) for the treatment of osteoporosis. Unfortunately, the process ends here.

Patient selection, proper up-titration, and insurance barriers must be considered by cardiologists and other physicians seeking to treat patients with the new combo medication.

Lack of guidelines and recommendations on use, ill-defined value of care, patient preference, and physicians’ lack of awareness are among the factors that can prevent widespread adoption of new medications.

Recent trials involving promising medications to treat patients with heart failure with preserved ejection fraction have not produced significant reductions in mortality.

Research results presented at HFSA 2016 support switching from conventional treatment approaches to the new combination treatment.

A presentation at the 2016 Heart Failure Society of America Scientific Meeting provided details on serelaxin, ularitide, and other new therapies for heart failure.

When a non-profit AIDS advocacy group offers as many programs as Gay Men's Health Crisis (GMHC) efficiency is a challenge. The organization relies on three management practices to remain efficient and audit-ready, particularly data-driven administrative supervision.

Pieter Muntendam, MD, scPharmaceuticals, and colleagues hoped their productive can help reduce patients' length of stay in the hospital.

At the Heart Failure Society of America's 20th Annual Scientific Meeting, Pieter Muntendam, MD, scPharmaceuticals, discussed his work in developing a hospital strength treatment option for patients with fluid overload using the well known drug furosemide, now for subcutaneous administration.

HIV AIDS is treatable but in rural areas the fear of people finding out an individual's HIV status can be a barrier. A University of Virginia Health System team has had success with training peer coaches to counsel such patients.

San Francisco, CA, with the backing of generous state Medicaid coverage, believes it can wipe out hepatitis C in vulnerable populations including people with HIV, intravenous drug users, homeless people, and prisoners in the city's jails.

According to Joseph Rogers, MD, Duke University, the HFSA has grown positively over the years to become a platform showcasing high level science, as evidenced through the late breakers that were presented.

Joseph Rogers, MD, Duke University discusses palliative care and how it fits into the overall treatment regimen of very sick patient populations.

Researchers reported black patients enrolled in the PARADIGM-HF study had more favorable prognostic baseline characteristics than white patients in the study. However, black patients exhibited a higher risk for cardiovascular death and hospitalizations.

Subcutaneously administered furosemide yields nearly identical outcomes compared with the traditional intravenous method of delivery, but is more convenient and well tolerated.

As the annual ECTRIMS conference in London wound down there was definitely a sense of optimism that there would be more good news to come before the group meets next October in Paris.

While there's no yet proven treatment for heart failure with preserved ejection fraction, the team is really aiming to understand the pathophysiology to design better targeted treatments.

Study results presented at the 2016 Heart Failure Society of America Scientific Meeting show that treatment with omecantiv mecarbil improved cardiac function and quality of life in patients with heart failure.

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

HIV/AODS research has tended to silo people into particular categories or particular communities like injecting drug users, men who have sex with men, etc.

"Heart failure is a disease that happens because of other diseases, so it's kind of the end result of diabetes, heart attacks, and cancer therapies, so it's hard to be a heart failure doctor and not spend a lot of time thinking about all the other medical specialties," concluded Allen.